DAN:NYSEDana Incorporated Analysis
Data as of 2026-08-15 - not real-time
$30.35
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Dana Incorporated is priced at $30.35 and its moving averages line up in bearish order, the shorter trailing the longer. The last 30 days have gained 21.8%. Relative strength is 61.7 — approaching overbought — and the MACD signal is bullish. Price has been bracketed by support at $25.95 and resistance at $31.20.
Multiples put this in undervalued territory at a P/E of 7.5. Sell-side targets cluster 23.3% above the current quote. Revenue is growing at 3.9% on a 14.6% profit margin. The 1.58% dividend yield looks stretched against payout coverage.
Risk scores 8 out of 10, which is high for this asset class. With 30-day volatility of 38.3%, a beta of 1.25 and a maximum drawdown of 36.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 4/10 conviction over the longer horizon.
Multiples put this in undervalued territory at a P/E of 7.5. Sell-side targets cluster 23.3% above the current quote. Revenue is growing at 3.9% on a 14.6% profit margin. The 1.58% dividend yield looks stretched against payout coverage.
Risk scores 8 out of 10, which is high for this asset class. With 30-day volatility of 38.3%, a beta of 1.25 and a maximum drawdown of 36.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 4/10 conviction over the longer horizon.
Top Market Events
Dana Incorporated NYSE: DAN will release its 2026 second-quarter financial results on Thursday, August 6, 2026.With EPS growth for the next five years forecasted at 128.Updated Jul 21, 2026 0 MAUMEE, Ohio, July 21, 2026 /PRNewswire/ -- Dana Incorporated NYSE: DAN announced today that its...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading above the 200-day average of 29.45
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Dividend yield of 1.58% looks stretched against payout coverage
- Trading above the 200-day average of 29.45
Long Term
> 3 yearsPositive
Model confidence: 4/10
Key Factors
- Dividend yield of 1.58% looks stretched against payout coverage
- Analyst targets imply +23.3% versus the current price
- Negative return on equity of -1.6%
Key Metrics & Analysis
Financial Health
Revenue Growth3.90%
Profit Margin14.55%
P/E Ratio7.5
ROE-1.63%
ROA2.80%
Debt/Equity75.79
P/B Ratio1.7
Op. Cash Flow$431.0M
Free Cash Flow$631.2M
Technical Analysis
TrendBearish
RSI61.7
Support$25.95
Resistance$31.20
MA 20$28.07
MA 50$28.69
MA 200$29.45
MACDBullish
VolumeIncreasing
Fear & Greed Index95.98
Valuation
Fair Value$78.65
Target Price$37.43
Upside/Downside23.32%
GradeUndervalued
TypeBlend
Dividend Yield1.58%
Risk Assessment
Beta1.25
Volatility38.27%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.